Skip to Content
Stock Analyst Update

Keeping Our Moderna FVE After In-Line Q1 Progress

Moderna shipped 102 million doses of mRNA-1273 in the first quarter, and reported sales of the vaccine of $1.7 billion in the quarter tracked closely with our $1.9 billion forecast.

Mentioned:

We're maintaining our $117 fair value estimate for Moderna (MRNA) following the release of first-quarter results and updated data for its COVID-19 vaccine program that largely fit with our prior assumptions. Moderna shipped 102 million doses of mRNA-1273 in the first quarter, and reported sales of the vaccine of $1.7 billion in the quarter tracked closely with our $1.9 billion forecast. Advance purchase agreements for 845 million doses (corresponding to $19.2 billion in sales) are now in place for 2021. We've slightly raised our full-year estimate to match this (from our prior estimate of $18.8 billion), but we've also slightly raised our estimates for capital expenditures to factor in additional investment in manufacturing capacity, leading to a neutral impact on our valuation. We continue to think that Moderna is still in the process of building a moat based on its mRNA technology leadership.

We're still assessing the competitive landscape in this novel field of vaccine and drug development, and while COVID-19 vaccine mRNA-1273 remains central to investors during the pandemic, we're focused on Moderna's ability to create novel, differentiated vaccines in CMV (entering phase 3 this year), Zika (entering phase 2), and several other phase 1 respiratory virus programs, including RSV and flu. Beyond vaccines, Moderna is continuing to enroll studies in oncology, cardiology, and rare diseases, which could create a significant new market for therapeutic mRNA. 

Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.

Karen Andersen does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.